Proprietary Aptegra™ platform reduces five assays to one Results in 66% faster testing time and significantly lower cost for clients compared to traditional methods Only platform that meets all regulatory requirements to establish CHO genetic stability with a single test SINGAPORE - Media OutReach Newswire - 17 April 2024 - Merck, a leading science and